Emergence of vancomycin resistance in Staphylococcus aureus

New England Journal of Medicine

Volumn 340, Issue 7, 1999, Pages 493-501

  Smith, Theresa L ^c   Pearson, Michele L ^b   Wilcox, Kenneth R ^c   Cruz, Cosme ^a   Lancaster, Michael V ^c   Robinson Dunn, Barbara ^c   Tenover, Fred C ^c   Zervos, Marcus J ^a   Band, Jeffrey D ^a   White, Elizabeth ^c   Jarvis, William R ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GENTAMICIN; METICILLIN; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PERITONITIS; BACTERIUM ISOLATION; CASE REPORT; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETES MELLITUS; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CONTACT TRACING; DIABETES COMPLICATIONS; DRUG RESISTANCE, MICROBIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FATAL OUTCOME; HUMANS; INFECTION CONTROL; KIDNEY FAILURE, CHRONIC; MALE; METHICILLIN RESISTANCE; MICHIGAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW JERSEY; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0033580208     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199902183400701     Document Type: Article

References (62)

1. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996;24:380-8.
2. Waldvogel FA. Staphylococcus aureus (including toxic shock syndrome). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:1754-77.
3. Atkinson BA, Lorian V. Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J Clin Microbiol 1984;20:791-6.
4. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
5. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329-34.
6. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195-8.
7. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
8. Garrett DO, Jochimsen E, Murfitt K, et al. The impending apocalypse, the emergence of vancomycin resistance in Staphylococcus spp. Infect Control Hosp Epidemiol 1997;18:Suppl:P32. abstract.
9. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
10. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and blood-stream infection. J Clin Microbiol 1990;28:2064-8.
11. Sanyal D, Johnson AP, George RC, Cookson BD, Williams AJ. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 1991; 337:54.
12. Aubert G, Passot S, Lucht F, Dorche G. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of S. epidermidis infection. J Antimicrob Chemother 1990;25:491-3.
13. Reduced susceptibility of Staphylococcus aureus to vancomycin -Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.
14. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
15. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - approved standard. 4th ed. Vol. 17. No. 2. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1997. (NCCLS publication no. M7-A4.)
16. Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 6th ed. Washington, D.C.: American Society for Microbiology, 1995:282-98.
17. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7. [Erratum, J Clin Microbiol 1998; 36:2167.]
18. Bannerman TL, Hancock GA, Tenover FC, Miller JM. Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus. J Clin Microbiol 1995;33:551-5.
19. Costerton JW, Irvin RT, Cheng K-J. The bacterial glycocalyx in nature and disease. Annu Rev Microbiol 1981;35:299-324.
20. Newman GR, Jasani B. Post-embedding immunoenzyme techniques. In: Polak JM, Varndell IM, eds. Immunolabelling for electron microscopy. Amsterdam: Elsevier Science, 1984:53-70.
21. Petersen NJ, Collins DE, Marshall JH. A microbiological assay technique for hands. Health Lab Sci 1973;10:18-22.
22. Jorgensen JH. Laboratory issues in the detection and reporting of antibacterial resistance. Infect Dis Clin North Am 1997;11:785-802.
23. Ingerman MJ, Santoro J. Vancomycin: a new old agent. Infect Dis Clin North Am 1989;3:641-51.
24. Bamberger DM. Outcome of medical treatment of bacterial abscesses without therapeutic drainage: review of cases reported in the literature. Clin Infect Dis 1996;23:591-603.
25. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
26. Mollitt DL. Pediatric surgical infection and antibiotic usage. Pediatr Infect Dis 1985;4:326-9.
27. Serry C, Bleck PC, Javid H, et al. Sternal wound complications: management and results. J Thorac Cardiovasc Surg 1980;80:861-7.
28. Hermans PE, Wilhelm MP. Vancomycin. Mayo Clin Proc 1987;62: 901-5.
29. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998;27:478-86.
30. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993;37:2311-7.
31. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992;166:1066-72.
32. Shlaes DM, Shlaes JH, Vincent S, Etter L, Fey PD, Goering RV. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother 1993;37:2432-7.
33. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995;44(RR-12):1-13.
34. Conte JE Jr, Cohen SN, Roe BB, Elashoff RM. Antibiotic prophylaxis and cardiac surgery: a prospective double-blind comparison of single-dose versus multiple-dose regimens. Ann Intern Med 1972;76:943-9.
35. Kacica MA, Horgan MJ, Ochoa L, Sandler R, Lepow ML, Venezia RA. Prevention of gram-positive sepsis in neonates weighing less than 1500 grams. J Pediatr 1994;125:253-8.
36. Kaplan AH, Gilligan PH, Facklam RR. Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol 1988;26:1216-8.
37. Lam TY, Vas SI, Oreopoulos DG. Long-term intraperitoneal vancomycin in the prevention of recurrent peritonitis during CAPD: preliminary results. Perit Dial Int 1991;11:281-2.
38. Ranson MR, Oppenheim BA, Jackson A, Kamthan AG, Scarffe JH. Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect 1990;15:95-102.
39. Henrickson KJ, Powell KR, Schwartz CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis 1988;157:600-1.
40. Schwartz CL, Henrickson KJ, Roghmann K, Powell KR. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 1990;8: 1591-7.
41. Henrickson KJ, Dunne WM Jr. Modification of central venous catheter flush solution improves in vitro antimicrobial activity. J Infect Dis 1992; 166:944-6.
42. Gaillard JL, Merlino R, Pajot N, et al. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. JPEN J Parenter Enteral Nutr 1990;14:593-7.
43. Spafford PS, Sinkin RA, Cox C, Reubens L, Powell KR. Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. J Pediatr 1994;125:259-63.
44. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
45. Shenep JL, Hughes WT, Roberson KP, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
46. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
47. Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia: randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986;81:237-42.
48. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8. [Erratum, J Infect Dis 1991; 164:832.]
49. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991;10:918-23.
50. Lamy T, Michelet C, Dauriac C, Grulois I, Donio PY, Le Prise PY. Benefit of prophylaxis by intravenous systemic vancomycin in granulocytopenic patients: a prospective, randomized trial among 59 patients. Acta Haematol 1993;90:109-13.
51. Isaacman DJ, Karasic RB. Lack of effect of changing needles on contamination of blood cultures. Pediatr Infect Dis J 1990;9:274-8.
52. Krumholz HN, Cummings S, York M. Blood culture phlebotomy: switching needles does not prevent contamination. Ann Intern Med 1990; 113:290-2. [Erratum, Ann Intern Med 1990;113:723.]
53. Strand CL, Wajsbort RR, Sturmann K. Effect of iodophor vs iodine tincture skin preparation on blood culture contamination rate. JAMA 1993;269:1004-6.
54. Gradon JD, Wu EH, Lutwick LI. Aerosolized vancomycin therapy facilitating nursing home placement. Ann Pharmacother 1992;26:209-10.
55. Weathers L, Riggs D, Santeiro M, Weibley RE. Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 1990;9:220-1.
56. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992;117: 297-302.
57. Bastani B, Freer K, Read D, et al. Treatment of gram-positive peritonitis with two intraperitoneal doses of vancomycin in continuous ambulatory peritoneal dialysis patients. Nephron 1987;45:283-5.
58. Newman LN, Tessman M, Hanslik T, Schulak J, Mayes J, Friedlander M. A retrospective view of factors that affect catheter healing: four years or experience. Adv Perit Dial 1993;9:217-22.
59. Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993;8:231-4.
60. Edell LS, Westby GR, Gould SR. An improved method of vancomycin administration to dialysis patients. Clin Nephrol 1988;29:86-7.
61. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8, 635.
62. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996;17:53-80. [Erratum, Infect Control Hosp Epidemiol 1996; 17:214.]